Sufentanil

Pre-existing respiratory depression, severe chronic obstructive pulmonary disease, cor pulmonale, or substantially decreased respiratory reserve increases the risk of fatal respiratory arrest. Sufentanil suppresses respiratory drive via MOR activation in the pre-Bötzinger complex and parabrachial nucleus.

In patients with head injury, intracranial lesions, or pre-existing elevated intracranial pressure, sufentanil-induced respiratory depression can exacerbate ICP elevation via hypercapnia-mediated cerebral vasodilation. Additionally, opioid-induced miosis and sedation may obscure neurological assessment.

Acute alcohol intoxication or delirium tremens combined with sufentanil creates additive respiratory and CNS depression risk. Standard opioid class contraindication.

Hepatic impairment reduces CYP3A4-mediated N-dealkylation of sufentanil to norsufentanil, decreasing clearance and increasing the risk of prolonged or excessive opioid effects including respiratory depression.

Known hypersensitivity to sufentanil citrate or any component of the formulation, or to other opioid agonists, constitutes an absolute contraindication per the FDA label.

Neonates show markedly prolonged sufentanil elimination (t½ ~434 min vs. ~164 min in adults) due to immature hepatic CYP3A4 activity and reduced protein binding (79% vs. 93%). Dose adjustment and extended monitoring are required.

Sufentanil must only be administered in settings with immediate access to airway management equipment, supplemental oxygen, and personnel trained in the management of respiratory depression. The FDA label restricts use to medically supervised settings.

Co-administration with strong CYP3A4 inhibitors increases sufentanil plasma concentrations, potentiating all effects including respiratory depression. Dose reduction and extended monitoring are necessary.

Opioids including sufentanil reduce gastrointestinal motility via peripheral MOR activation. Administration in the setting of known or suspected paralytic ileus may worsen obstruction.

Combined use of opioids with MAOIs is a general class contraindication. While sufentanil does not interact with serotonin systems (unlike meperidine or tramadol), the potential for unpredictable potentiation of CNS depression warrants avoidance. No sufentanil-specific MAOI interaction data exist.